[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"malignant-neoplasm\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:malignant-neoplasm":27},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,48,0,25,[9,41,64,85,109,130,151,163,190,211,230,250,262,285,307,347,369,388,416,435,457,482,503,530,590],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100053831","phase-2-a-study-of-mk-5684-in-people-with-certain-solid-tumors-mk-5684-015omaha-015-100053831",false,"NCT06979596","A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015\u002FOMAHA-015)","A Multicenter, Open-label, Phase 2 Basket Study of MK-5684 in Participants With Selected Solid Tumors (OMAHA-015)","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Cohort A:\n\n  * Has a diagnosis of hormone receptor positive\u002FHuman Epidermal Growth Factor Receptor 2 negative (HR+\u002FHER2-) invasive breast carcinoma that is either locally advanced disease not amenable to resection with curative intent (herein called unresectable) or metastatic disease not treatable with curative intent.\n  * Has experienced disease progression on or after at least 1 prior endocrine-based therapy in the metastatic setting and received either, 1 line of an approved protocol-specified combination endocrine-based therapy, or 2 or more lines of protocol-specified endocrine-based therapy in the metastatic setting\n* Cohort B:\n\n  * Has histologically confirmed high-grade epithelial (including high-grade serous or predominantly serous, high-grade endometrioid, malignant mixed Müllerian tumors \\[carcinosarcoma\\], or clear cell) ovarian, fallopian tube, or primary peritoneal carcinoma.\n  * Has received between 4 to 8 cycles of platinum-based doublet chemotherapy in third-line (3L) setting for ovarian cancer.\n* Cohort C:\n\n  * Histologically confirmed diagnosis of primary advanced or recurrent low-grade endometrioid carcinoma (eg, Federation of Gynecology and Obstetrics \\[FIGO\\] Grade 1\u002F2, or well\u002Fmoderately differentiated).\n  * Treatment naïve or has received up to 1 prior line of platinum-based therapy in either the advanced\u002Fmetastatic OR adjuvant\u002Fneoadjuvant setting.\n* All Cohorts :\n\n  * Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline.\n  * Human immunodeficiency virus (HIV)-infected participants must have well controlled HIV on antiretroviral therapy.\n  * Participants who are Hepatitis B surface antigen positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load.\n  * Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable.\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Cohort A:\n\n  * Breast cancer amenable to treatment with curative intent.\n  * Has advanced\u002Fmetastatic, symptomatic visceral spread at risk of rapidly evolving into life-threatening complications, such as lymphangitic lung metastases, radiographic evidence of intratumoral cavitation or invasion\u002Finfiltration of a major blood vessel, bone marrow replacement, carcinomatous meningitis, significant symptomatic liver metastases, symptomatic pericardial effusion, symptomatic peritoneal carcinomatosis, or the need to achieve rapid symptom control.\n* Cohort B:\n\n  * Has nonepithelial cancers (germ cell tumors and sex cord-stromal tumors), borderline tumors (low malignant potential), mucinous, seromucinous that is predominantly mucinous, malignant Brenner's tumor, low-grade serous, low-grade endometrioid, and undifferentiated carcinoma.\n  * Has platinum-resistant ovarian cancer (defined as disease that has progressed per radiographic imaging within 180 days after the last dose of first-line \\[1L\\] platinum-based therapy) or platinum-refractory ovarian cancer (defined as disease that has progressed per radiographic imaging while receiving or within 28 days of the last dose of 1L platinum based therapy).\n  * Is a candidate for curative-intent surgery or curative-intent radiotherapy for ovarian cancer.\n* Cohort C:\n\n  * Has high-grade (FIGO Grade 3 or poorly differentiated) endometrioid carcinoma and nonendometrioid histologies of any type (including serous, clear cell, mixed, carcinosarcoma), and neuroendocrine tumors are not eligible. Uterine mesenchymal tumors such as an endometrial stromal sarcoma, leiomyosarcoma, or other types of pure sarcomas, and adenosarcomas are not eligible.\n  * Is a candidate for curative-intent surgery or curative-intent radiotherapy.\n* All Cohorts:\n\n  * Has confirmed or suspected adrenal metastases.\n  * Has known difficulty in tolerating oral medications, unable to swallow orally administered medication, or conditions which would impair absorption of oral medications.\n  * Has any prior history or current condition of adrenal insufficiency.\n  * HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease.\n  * Has received a live or live-attenuated vaccine within 30 days before the first dose of study intervention. Administration of killed vaccines is allowed.\n  * Has a known additional malignancy that is progressing or has required active treatment within the past 3 years.\n  * Has known active central nervous system metastases and\u002For carcinomatous meningitis.\n  * Has a history of stem cell\u002Fsolid organ transplant.\n  * Has not adequately recovered from major surgery or has ongoing surgical complications.","ALL","18 Years",{"count":20,"type":21},250,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","Researchers want to learn if MK-5684 (the study medicine) can treat breast cancer, ovarian cancer, and endometrial cancer. MK-5684, the study medicine, is designed to treat cancer by blocking the body from making steroid hormones.\n\nResearchers will compare MK-5684 to the standard treatments for each cancer type in this study.\n\nThe goal of this study is to learn if people who receive MK-5684 live longer without the cancer growing or spreading compared to people who receive a standard treatment.",[27],"Malignant Neoplasm","RECRUITING","2026-07-10",{"date":31,"type":32},"2026-07-13","ACTUAL",{"date":34,"type":32},"2025-08-11",{"date":36,"type":21},"2027-11-04",{"name":38,"class":39},"Merck Sharp & Dohme LLC","INDUSTRY",57,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":49,"targetDuration":4,"studyType":22,"phases":51,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":57,"startDateStruct":58,"completionDateStruct":60,"leadSponsor":62,"locationsCount":63},"100053225","phase-1-a-study-of-pembrolizumab-in-japanese-pediatric-participants-with-solid-tumors-or-lymphomas-and-japanese-adult-participants-with-merkel-cell-carcinoma-mk-3475-g21keynote-g21-100053225","NCT07302347","A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21\u002FKEYNOTE-G21)","A Phase I\u002FII Study of Pembrolizumab (MK-3475) in Japanese Pediatric Participants With Specific Solid Tumors or Lymphomas, or in Japanese Adult Participants With Advanced Merkel Cell Carcinoma (KEYNOTE-G21)","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\nArm 1:\n\n* For participants with relapsed or refractory classical Hodgkin lymphoma (cHL) or primary mediastinal large B-cell lymphoma (PMBCL)\n\n  * Has a confirmed diagnosis of relapsed or refractory cHL or PMBCL after the most recent therapy\n  * Has radiographically measurable disease per Lugano classification\n* For participants with completely resected melanoma:\n\n  * Has surgically completely resected and histologically\u002Fpathologically confirmed diagnosis of Stage IIB, IIC, III or IV cutaneous melanoma\n  * Has not received any prior systemic therapy for their melanoma beyond surgical resection\n  * All suspicious lesions amenable to biopsy are confirmed negative for malignancy\n* For participants with locally advanced or metastatic melanoma:\n\n  * Has histologically confirmed diagnosis of locally advanced (unresectable Stage III) or metastatic (Stage IV) melanoma (including acral) not amenable to local therapy\n  * Has radiographically measurable lesion(s) as defined by RECIST 1.1\n* For participants with microsatellite instability-high (MSI-H)\u002Fmismatch repair deficiency (dMMR) solid tumors:\n\n  * Has histologically\u002Fcytologically documented, locally-advanced, or metastatic solid malignancy that is incurable and has either (a) failed prior standard therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the participant and treating physician\n  * Has a documented positive local MSI-H or dMMR test result\n  * Has radiographically measurable disease based on RECIST 1.1\n* For participants with tumor mutational burden-high (TMB-H) solid tumors:\n\n  * Has histologically\u002Fcytologically documented, locally-advanced, or metastatic solid malignancy that is incurable and has either (a) failed prior standard therapy, (b) for which no standard therapy exists, or (c) standard therapy is not considered appropriate by the participant and treating physician\n  * Has radiographically measurable disease based on RECIST 1.1\n* For participants with MCC:\n\n  * Has histologically confirmed diagnosis of locoregional MCC that has recurred following standard locoregional therapy with surgery and\u002For radiation therapy and is not amenable to local therapy or metastatic MCC (Stage IV)\n  * Has radiographically measurable disease based on RECIST 1.1\n\nArm 2:\n\n* For participants with MCC:\n\n  * Has been untreated for advanced or metastatic disease\n\nArm 1 \\& Arm 2:\n\n* Life expectancy of \\>3 months (Arm 1) or \\>6 months (Arm 2)\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has known additional malignancy that is progressing or has required active treatment\n* Has known active (central nervous system) CNS metastases and\u002For carcinomatous meningitis\n* Has active autoimmune disease that has required systemic treatment in past 2 years\n* Has history of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease\n* Has active infection requiring systemic therapy\n* Has known history of human immunodeficiency virus (HIV) infection\n* Has known history of Hepatitis B infection or known active Hepatitis C virus\n* Has undergone solid organ transplant at any time, or prior allogeneic hematopoietic stem cell transplantation within the last 5 years\n* Has not adequately recovered from major surgery or has ongoing surgical complications","6 Months",{"count":50,"type":21},20,[52,24],"PHASE1","Researchers are looking for new ways to treat people with solid tumors, lymphomas (blood cancers), and a certain type of skin cancer. The goals of this study are to learn:\n\n* About the safety of pembrolizumab (the study medicine) and if people tolerate it\n* What happens to different doses of pembrolizumab in a person's body over time\n* How the cancer responds (gets smaller or goes away) to treatment",[27,55,56],"Carcinoma, Merkel Cell","Lymphoma",{"date":31,"type":32},{"date":59,"type":32},"2026-06-23",{"date":61,"type":21},"2029-12-31",{"name":38,"class":39},7,{"id":65,"slug":66,"hasResults":12,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":84},"100640684","phase-1-clinical-study-of-mk-4884-in-participants-with-advanced-or-metastatic-solid-tumors-mk-4884-001-100640684","NCT07600749","Clinical Study of MK-4884 in Participants With Advanced or Metastatic Solid Tumors (MK-4884-001)","A Phase 1 Open-label, Multicenter Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of MK-4884 in Participants With Advanced\u002FMetastatic Solid Tumors","Inclusion Criteria:\n\n* Has a histologically or cytologically confirmed diagnosis of 1 of the following unresectable (locally advanced) and\u002For advanced (metastatic) solid tumors:\n* Colorectal carcinoma (CRC)\n* Renal cell carcinoma (RCC) that contains a clear cell component (with or without sarcomatoid and\u002For rhabdoid features)\n* Nonsquamous non-small cell lung cancer (NSCLC)\n* Biliary tract cancer (BTC) (intra-or extrahepatic cholangiocarcinoma (CCA)) or gallbladder cancer (GBC)\n* Has measurable disease by Response Evaluation Criteria In Solid Tumors 1.1 (RECIST 1.1)\n* Has adequate organ function\n* Participants with human immunodeficiency virus (HIV) infection must have well controlled HIV on stable antiretroviral therapy (ART) for at least 4 weeks\n* Participants who are hepatitis B surface antigen (HBsAg) positive are eligible if they have received Hepatitis B virus (HBV) antiviral therapy for at least 4 weeks, and have undetectable HBV viral load\n* Participants with a history of Hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable\n\nExclusion Criteria:\n\n* Has gastrointestinal malabsorption, a surgical procedure or a condition that could affect the absorption of the study drug\n* Has a history of clinically significant cardiac, cardiovascular and\u002For cerebrovascular disease\n* Has a serious nonhealing wound, ulcer, or bone fracture\n* Has an active infection(s) requiring systemic therapy\n* HIV-infected participants with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Known additional malignancy that is progressing or has required active treatment within the past 2 years\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Has a history of stem cell\u002Fsolid organ transplant\n* Has not adequately recovered from major surgery",{"count":72,"type":21},120,[52],"Researchers are looking for new ways to treat certain types of advanced and\u002For metastatic solid tumors.\n\nThe main goal of this study is to learn about the safety of different doses of MK-4884 and if participants tolerate them.",[27],"2026-06-25",{"date":78,"type":32},"2026-06-29",{"date":80,"type":32},"2026-06-18",{"date":82,"type":21},"2029-10-04",{"name":38,"class":39},4,{"id":86,"slug":87,"hasResults":12,"nctId":88,"briefTitle":89,"officialTitle":90,"acronym":4,"eligibilityCriteria":91,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":92,"targetDuration":4,"studyType":22,"phases":94,"briefSummary":95,"conditions":96,"keywords":97,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":101,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},"100612373","phase-2-keymaker-u01-substudy-01j-a-study-of-pembrolizumab-plus-mk-1084-in-participants-with-non-small-cell-lung-cancer-nsclc-with-kirsten-rat-sarcoma-viral-oncogene-homolog-kras-g12c-mutations-mk-3475-01jkeymaker-u01j-100612373","NCT07252739","KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J\u002FKEYMAKER-U01J)","KEYMAKER-U01 Substudy 01J: A Randomized Phase 2 Umbrella Study With Rolling Arms of Investigational Agents for First-line Treatment of Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With KRAS G12C Mutations","Inclusion Criteria:\n\nThe main inclusion criteria include but are not limited to the following:\n\n* Has histologically or cytologically confirmed diagnosis of advanced or metastatic nonsquamous Non-Small Cell Lung Cancer (NSCLC)\n* Has tumor tissue or circulating tumor deoxyribonucleic acid (ctDNA) that demonstrates the presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C mutations\n* Can provide an archival tumor tissue sample or newly obtained core, incisional, excisional biopsy of a tumor lesion not previously irradiated\n* Has recovered to ≤Grade 1 or baseline from any Adverse events (AEs) due to previous anticancer therapies and\u002For ≤Grade 2 neuropathy and\u002For endocrine-related AEs adequately treated with hormone replacement\n* Has well controlled human immunodeficiency virus (HIV) on antiretroviral therapy (ART) if HIV-infected\n* Has undetectable hepatitis B (HBV) viral load and have received HBV antiviral therapy for at least 4 weeks if hepatitis B surface antigen (HBsAg) positive\n* Has undetectable hepatitis C (HCV) viral load if HCV-infected\n\nExclusion Criteria:\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a diagnosis of small cell lung cancer or, for mixed tumors, presence of small cell elements\n* Has HIV-infection with a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous clear history of inflammatory bowel disease\n* Has uncontrolled, clinically significant cardiovascular disease or cerebrovascular disease, including New York Heart Association Class III or IV congestive heart failure, unstable angina, myocardial infarction, uncontrolled symptomatic arrhythmia, prolongation of corrected QT interval corrected for heart rate by Fridericia's formula (QTcF) interval to \\>470 ms, and\u002For other serious cardiovascular and cerebrovascular diseases within the 6 months preceding study intervention\n* Has received prior systemic anticancer therapy for advanced or metastatic NSCLC\n* Has received any prior immunotherapy and was discontinued from that treatment due to a Grade 3 or higher immune-related adverse event (irAE) (except endocrine disorders that can be treated with replacement therapy) or was discontinued from that treatment due to Grade 2 myocarditis or recurrent Grade 2 pneumonitis\n* Has received previous treatment with an agent targeting KRAS\n* Has received prior systemic anticancer therapy within 4 weeks or 5 half-lives (whichever is shorter) and has not recovered to grade ≤ 1 or baseline from AE associated with anticancer therapy before allocation\u002Frandomization\n* Has received radiation therapy to the lung that is \\>30 Gray within 6 months of start of study intervention\n* Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention\n* Has a known additional malignancy that is progressing or has required active treatment within the past 3 years\n* Has a known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Has an active autoimmune disease that has required systemic treatment in the past 2 years. Replacement therapy (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed\n* Has a history of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease\n* Has a history of stem cell\u002Fsolid organ transplant\n* Has not adequately recovered from major surgery or has ongoing surgical complications",{"count":93,"type":21},130,[24],"Researchers want to learn if using a study medicine called MK-1084 can help treat NSCLC. MK-1084 is a type of treatment called targeted therapy for the Kirsten rat sarcoma viral oncogene homolog (KRAS) G12C gene change. The goal of this study is to learn about the safety of MK-1084 and to learn how many people have the cancer get smaller or go away during the study treatment.",[27],[98,99,100],"Programmed Cell Death-1 (PD1, PD-1)","Programmed Cell Death 1 Ligand 1 (PDL1, PD-L1)","Programmed Cell Death 1 Ligand 2 (PDL2, PD-L2)",{"date":102,"type":32},"2026-06-26",{"date":104,"type":32},"2025-12-19",{"date":106,"type":21},"2033-01-14",{"name":38,"class":39},33,{"id":110,"slug":111,"hasResults":12,"nctId":112,"briefTitle":113,"officialTitle":113,"acronym":4,"eligibilityCriteria":114,"healthyVolunteers":115,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":116,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":121,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":129},"100376777","molecular-genetics-studies-of-cancer-patients-and-their-relatives-100376777","NCT04185935","Molecular Genetics Studies of Cancer Patients and Their Relatives","Inclusion Criteria:\n\n* Individuals must have a personal history of cancer and\u002For a family history of cancer suggestive of the presence of an inherited predisposition. This inherited predisposition might manifest as:\n\n  * Young age cancer diagnosis\n  * Multiple primary neoplasms in affected member\n  * The presence of rare tumor types in the family\n  * Congenital malformations\n  * Any other family clustering of cancer\n  * Any other cancer-predisposing genetic diseases\u002Fconditions\n* Individuals may also be eligible by participation in the City of Hope Cancer Screening \\& Prevention Program Network (CSPPN) clinical service or on the basis of membership in a group known or suspected to have an increased risk of carrying a genetic alteration or of sustaining a particular exposure that would place that at increased risk of cancer. (Examples would include members of occupational cohorts like asbestos workers, individuals with multiple dysplastic nevi in the absence of a family history of cancer, and individuals descended from a particular tribe in the American Southwest who have an increased incidence of a rare genetic alteration associated with an increased risk of a specific cancer.)\n* Individuals and families may be referred to us in a number of different ways. After initial contact is made with a individual or family by family studies personnel; an individual within the bloodline will be identified as the historian. There may be more than one historian within a family\n* At least one historian must be wiling to provide information or access as needed to contact appropriate family members for documentation of cancer and for consent. An individual is considered to be eligible to participate if they criteria; contact with relatives is not always indicated\n* Individuals who are under 18 are eligible for study if they meet the criteria. Consent for participation must be given by a legal guardian or parent\n* Deceased patients may be included in the study. Public records, such as death certificates, can be used to confirm information from individuals or family members. If medical records are needed, consent for these records will be obtained from the deceased's next of kin. Next of kin refers to the following hierarchy of relatives; spouse, offspring, parents, and siblings. (Any further use of next of kin in this protocol should relate back to this hierarchy.) Archived tissue samples, such as pathology blocks or snap frozen tumor from a pathology department tumor bank (discard specimens) may be used for genetic research\n\nExclusion Criteria:\n\n* A family may be ineligible for study if the historian will not allow access to anyone within the family and thus, the accuracy of the family history cannot be established",true,{"count":117,"type":21},999999,"OBSERVATIONAL","This trial studies the genetic and behavioral factors that may contribute to the development of specific cancers and how these factors may affect the outcome of the disease in patients with a history of cancer and their relatives.",[27],{"date":78,"type":32},{"date":123,"type":32},"1997-04-18",{"date":125,"type":21},"2033-08-18",{"name":127,"class":128},"City of Hope Medical Center","OTHER",42,{"id":131,"slug":132,"hasResults":12,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":12,"sex":17,"minAge":137,"maxAge":138,"enrollmentInfo":139,"targetDuration":4,"studyType":22,"phases":141,"briefSummary":142,"conditions":143,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":144,"startDateStruct":145,"completionDateStruct":147,"leadSponsor":149,"locationsCount":150},"100588428","phase-1-a-study-of-patritumab-deruxtecan-in-pediatric-participants-with-relapsed-or-refractory-solid-tumors-mk-9999-01clightbeam-u01-100588428","NCT06941272","A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C\u002FLIGHTBEAM-U01)","LIGHTBEAM-U01 Substudy 01C: A Phase 1\u002F2 Substudy to Evaluate the Safety and Efficacy of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors","The main inclusion criteria include but are not limited to the following:\n\n* Has one of the following histologically confirmed advanced or metastatic solid tumors: Rhabdomyosarcoma (RMS), or Hepatoblastoma\n* Has progressed after at least 1 prior systemic treatment for RMS or hepatoblastoma and who has no satisfactory alternative treatment option (ie, is ineligible for other standard treatment regimens)\n* Participants who have adverse events (AEs) due to previous anticancer therapies must have recovered to Grade ≤1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have Grade ≤2 neuropathy are eligible. Participants with Grade ≤2 alopecia are also eligible\n* Hepatitis B surface antigen (HBsAg) positive participants are eligible if they have received hepatitis B virus (HBV) antiviral therapy and have undetectable HBV viral load\n* Participants with a history of hepatitis C virus (HCV) infection are eligible if HCV viral load is undetectable\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has a history of (noninfectious) interstitial lung disease (ILD)\u002Fpneumonitis that required steroids or has current ILD\u002Fpneumonitis, and\u002For suspected ILD\u002Fpneumonitis that cannot be ruled out by standard diagnostic assessments\n* Has clinically severe respiratory compromise resulting from intercurrent pulmonary illness\n* Has a history of solid organ transplant\n* Has a history of allogeneic stem cell transplant\n* Has clinically significant corneal disease\n* Has known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\u002Fleptomeningeal disease; participants with previously treated brain metastases may participate provided they are radiologically stable (ie, without evidence of progression) for at least 4 weeks\n* Has uncontrolled or significant cardiovascular disorder\n* Has a history of clinically significant congenital cardiac syndrome\n* Has a history of human immunodeficiency virus (HIV) infection\n* Has a known additional malignancy that is progressing or has required active treatment within the past 1 year\n* Has an active infection requiring systemic therapy\n* Has concurrent active hepatitis B (HBsAg positive and\u002For detectable HBV deoxyribonucleic acid \\[DNA\\]) and HCV defined as anti-HCV antibody (Ab) positive and detectable HCV ribonucleic acid \\[RNA\\]) infection\n* Has not adequately recovered from major surgery or have ongoing surgical complications","1 Month","17 Years",{"count":140,"type":21},50,[52,24],"Researchers are looking for new ways to treat children with hepatoblastoma or rhabdomyosarcoma (RMS) that has relapsed or is refractory:\n\n* Hepatoblastoma is a common liver cancer in babies and very young children\n* RMS is a cancer that starts in muscle cells, often in a child's head and neck, bladder, arms, or legs\n* Relapsed means the cancer came back after treatment\n* Refractory means the cancer did not respond (get smaller or go away) to treatment\n\nThe study treatment HER3-DXd (also known as MK-1022 or patritumab deruxtecan) is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn:\n\n* About the safety of HER3-DXd in children and if they tolerate it\n* What happens to HER3-DXd in children's bodies over time\n* If children who receive HER3-DXd have the cancer get smaller or go away",[27],{"date":59,"type":32},{"date":146,"type":32},"2025-05-26",{"date":148,"type":21},"2030-12-30",{"name":38,"class":39},61,{"id":152,"slug":4,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":17,"minAge":48,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":154,"briefSummary":53,"conditions":155,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":157,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":162,"locationsCount":63},"100616187",{"count":50,"type":21},[52,24],[27,55,56],"2026-06-10",{"date":158,"type":32},"2026-06-12",{"date":160,"type":21},"2026-06-30",{"date":61,"type":21},{"name":38,"class":39},{"id":164,"slug":165,"hasResults":12,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":22,"phases":172,"briefSummary":173,"conditions":174,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":156,"lastUpdatePostDateStruct":182,"startDateStruct":183,"completionDateStruct":185,"leadSponsor":187,"locationsCount":189},"100245918","phase-2-cytotoxic-t-lymphocytes-in-treating-patients-with-malignancies-with-bk-andor-jc-virus-100245918","NCT02479698","Cytotoxic T Lymphocytes in Treating Patients With Malignancies With BK and\u002For JC Virus","Phase II Study Assessing the Effect of BK Specific CTL Lines Generated by Ex Vivo Expansion in Patients With BK Virus Infection and JC Virus Infection","Inclusion Criteria:\n\n* Patients ≥ 2 years. English and non-English speaking patients are eligible.\n* Immunocompromised patients; and\u002For Non-immunocompromised patients with PML\u002FJC virus Encephalitis; and\u002For patients with any type of malignancies; and\u002For HIV\u002FAIDs; and\u002For history of solid organ transplant; and\u002For Merkel polyoma-virus related Merkel cell tumor(s) with measurable disease on imaging per RECIST criteria.\n* Patients with microscopic hematuria OR biopsy proven BK nephritis and urine or blood PCR positive for BK virus and\u002For JC viral encephalitis and\u002For JC end-organ disease and\u002For polyomavirus.\n* Clinical status at enrollment to allow tapering of steroids to less than 0.5 mg\u002Fkg\u002Fday of prednisone.\n* Patients who are currently receiving treatment with cidofovir, leflunomide, or other antiviral therapy with no response, will be eligible for CTL infusion.\n* Written informed consent and\u002For signed assent from patient, parent or guardian. Patients with cognitive impairments are eligible.\n* Negative pregnancy test in female patients of childbearing potential, defined as not post-menopausal for 12 months or no previous surgical sterilization. Women of child bearing potential must be willing to use an effective contraceptive measure while on study.\n* Patients enrolled on this study may be enrolled on other IND studies at the discretion of the PI.\n* Patients may be re-enrolled in the protocol should the infection re-occur, provided they meet all the other eligibility criteria at the moment of re-enrollment.\n\nExclusion Criteria:\n\n* Patients receiving prednisone \\> 0.5 mg\u002Fkg\u002Fday at time of enrollment, or have received ATG within 14 days or have received donor lymphocyte infusion (DLI) or Campath within 28 days of enrollment.\n* Patients with other uncontrolled infections (except HIV\u002FAIDS). For bacterial infections, patients must be receiving definitive therapy and have no signs of progressing infection for 72 hours prior to enrollment. For fungal infections patients must be receiving definitive systemic anti-fungal therapy and have no signs of progressing infection for 1 week prior to enrollment. Progressing infection is defined as hemodynamic instability attributable to sepsis or new symptoms, worsening physical signs or radiographic findings attributable to infection. Persisting fever without other signs or symptoms will not be interpreted as progressing infection\n* Patients with active acute (GVHD) grades II-IV",{"count":171,"type":21},100,[24],"This phase II trial studies how well donor cytotoxic T lymphocytes work in treating patients with malignancies with BK and\u002For JC virus. Cytotoxic T lymphocytes are made from donated blood cells that are grown in the laboratory and are designed to kill viruses that can cause infections in transplant patients and may be an effective treatment in patients with malignancies with BK and\u002For JC virus.",[175,176,177,178,27,179,180,181],"Acquired Immunodeficiency Syndrome","BK Virus Infection","Human Immunodeficiency Virus","JC Virus Infection","Merkel Cell Carcinoma","Merkel Cell Polyomavirus Infection","Viral Encephalitis",{"date":158,"type":32},{"date":184,"type":32},"2015-07-23",{"date":186,"type":21},"2027-07-31",{"name":188,"class":128},"M.D. Anderson Cancer Center",1,{"id":191,"slug":192,"hasResults":12,"nctId":193,"briefTitle":194,"officialTitle":195,"acronym":4,"eligibilityCriteria":196,"healthyVolunteers":12,"sex":17,"minAge":137,"maxAge":138,"enrollmentInfo":197,"targetDuration":4,"studyType":22,"phases":199,"briefSummary":200,"conditions":201,"keywords":4,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":204,"startDateStruct":206,"completionDateStruct":208,"leadSponsor":210,"locationsCount":4},"100639965","phase-1-a-study-of-ifinatamab-deruxtecan-in-pediatric-participants-with-relapsed-or-refractory-solid-tumors-mk-9999-01dlightbeam-u01-100639965","NCT07630974","A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D\u002FLIGHTBEAM-U01)","LIGHTBEAM-U01 Substudy 01D: A Phase 1b\u002F2 Substudy to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors","The main inclusion criteria include but are not limited to the following:\n\n* In Part 1, participant has recurrent or relapsed, refractory solid tumors (excluding primary central nervous system (CNS)); and in Part 2, participant has recurrent or relapsed, refractory and histologically confirmed diagnosis of osteosarcoma (OST), neuroblastoma (NBL), rhabdomyosarcoma (RMS), or Wilms tumor (WT). All participants must meet the following criteria: Has documented radiological disease progression after at least 1 line of prior therapy in the locally advanced\u002Fmetastatic setting and who has no satisfactory alternative treatment option (ie, is ineligible for other standard treatment regimens).\n* Is an individual of any sex\u002Fgender, ≥1 month to \\\u003C12 years of age for Part 1 and ≥1 month to \\\u003C18 years for Part 2 at the time of providing the informed consent or assent, as applicable\n* Participants who have AEs due to previous anticancer therapies must have recovered to ≤Grade 1 or baseline. Participants with endocrine-related AEs who are adequately treated with hormone replacement or participants who have ≤Grade 2 neuropathy are eligible.\n\nThe main exclusion criteria include but are not limited to the following:\n\n* Has clinically significant corneal disease\n* Has a history of cerebrovascular accident, transient ischemic attack, or another arterial thromboembolic event within 6 months before screening\n* Has uncontrolled or significant cardiovascular disease, including conduction abnormalities, hypertension, ischemic heart disease, heart failure, and peripheral vascular disease\n* Has any history of interstitial lung disease (ILD)\u002Fpneumonitis, irrespective of steroid use, except for a history of radiation pneumonitis that did not require steroids, current ILD, or Clinical or radiographic suspicion of ILD for which the diagnosis of ILD cannot be ruled out\n* Has clinically severe respiratory compromise resulting from intercurrent pulmonary illnesses\n* Has an active, known or suspected autoimmune disease.\n* Has history of solid organ transplant.\n* Has history of allogeneic stem cell transplant (SCT).\n* Has known active CNS metastases and\u002For carcinomatous meningitis\u002Fleptomeningeal disease\u002Fspinal cord compression. Participants with untreated and asymptomatic brain metastases or previously treated brain metastases may participate provided they are radiologically stable, (i.e, without evidence of progression) for at least 4 weeks\n* Has history of human immunodeficiency virus (HIV) infection.\n* Has known additional malignancy that is progressing or has required active treatment within the past 1 year.\n* Has active infection requiring systemic therapy\n* Has known hypersensitivity or contraindication to either the study intervention substance or inactive ingredients in the study intervention product\n* Participants who have not adequately recovered from major surgery or have ongoing surgical complications",{"count":198,"type":21},134,[52,24],"Researchers are looking for new ways to treat children with relapsed or refractory solid tumors:\n\n* Relapsed means the cancer came back after treatment\n* Refractory means the cancer did not respond (get smaller or go away) to treatment\n* Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids\n\nThe study treatment I-DXd (also known as MK-2400 or ifinatamab deruxtecan) is an antibody-drug conjugate (ADC). An ADC attaches to a protein on cancer cells and delivers treatment to destroy those cells. The goals of this study are to learn:\n\n* About the safety of I-DXd and if children younger than 12 years old tolerate it\n* How many children who receive I-DXd have the cancer get smaller or go away",[27],"NOT_YET_RECRUITING","2026-06-01",{"date":205,"type":32},"2026-06-05",{"date":207,"type":21},"2026-07-28",{"date":209,"type":21},"2031-08-17",{"name":38,"class":39},{"id":212,"slug":213,"hasResults":12,"nctId":214,"briefTitle":215,"officialTitle":216,"acronym":4,"eligibilityCriteria":217,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":218,"targetDuration":4,"studyType":22,"phases":219,"briefSummary":220,"conditions":221,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":203,"lastUpdatePostDateStruct":222,"startDateStruct":224,"completionDateStruct":226,"leadSponsor":228,"locationsCount":229},"100611940","phase-1-a-clinical-study-of-mk-4716-in-people-with-certain-solid-tumors-mk-4716-001-100611940","NCT07247110","A Clinical Study of MK-4716 in People With Certain Solid Tumors (MK-4716-001)","A Phase 1, Open-Label, Multicenter Study to Assess Safety, Tolerability, Pharmacokinetics, and Efficacy of MK-4716 as Monotherapy and as Part of Combination Therapy in Participants With KRAS-Altered Advanced or Metastatic Solid Tumors","Inclusion Criteria:\n\n* Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Has a confirmed diagnosis of locally advanced unresectable or metastatic solid tumor\n* Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Must demonstrate presence of Kirsten rat sarcoma viral oncogene homolog (KRAS) alteration\n* Subset of arm MK-4716 Dose Escalation and subset of arm MK-4716 + Cetuximab: Has received at least 1 prior line of systemic therapy for locally advanced unresectable or metastatic disease\n* Arm MK-4716 + Pembrolizumab: Has a confirmed diagnosis of metastatic non-small cell lung cancer\n* Arm MK-4716 + Pembrolizumab: Must demonstrate presence of KRAS alteration\n* Arm MK-4716 + Pembrolizumab: Must be untreated\n* Has measurable disease\n* Has the ability to swallow and retain oral medication\n\nExclusion Criteria:\n\n* Arm MK-4716 + Pembrolizumab: Has a diagnosis of immunodeficiency or is receiving chronic systemic steroid therapy (in dosing exceeding 10 mg daily of prednisone equivalent) or any other form of immunosuppressive therapy within 7 days prior to the first dose of study intervention\n* Arm MK-4716 + Pembrolizumab: Has received any prior immunotherapy and was discontinued from that treatment\n* Arm MK-4716 + Pembrolizumab: Has active autoimmune disease that has required systemic treatment in the past 2 years. Hormonal supplementation (eg, thyroxine, insulin, or physiologic corticosteroid) is allowed\n* History of human immunodeficiency virus infection\n* Has a known additional malignancy that is progressing or has required active treatment within the past 2 years\n* Has a known active central nervous system metastases and\u002For carcinomatous meningitis\n* History of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease\n* Has active infection requiring systemic therapy\n* Has Hepatitis B or Hepatitis C virus infection\n* History of stem cell\u002Fsolid organ transplant\n* Has not adequately recovered from major surgery or has ongoing surgical complications",{"count":20,"type":21},[52],"Researchers are looking for new ways to treat certain advanced or metastatic solid tumors. The goal of this study is to learn about the safety of MK-4716 and if people tolerate it when taken alone or with other treatments.",[27],{"date":223,"type":32},"2026-06-03",{"date":225,"type":32},"2025-12-16",{"date":227,"type":21},"2030-12-01",{"name":38,"class":39},19,{"id":231,"slug":232,"hasResults":12,"nctId":233,"briefTitle":234,"officialTitle":235,"acronym":4,"eligibilityCriteria":236,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":237,"targetDuration":4,"studyType":22,"phases":239,"briefSummary":240,"conditions":241,"keywords":4,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":189},"100376433","phase-2-nasal-inhalation-of-isopropyl-alcohol-for-the-treatment-of-nausea-in-patients-with-cancer-100376433","NCT04181463","Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer","Inhalation Approaches to Nausea: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Rate current severity of acute\u002Fchronic nausea \\>= 4 on NRS (Numeric Rating Scale)\n* Diagnosis of cancer\n* Able to read\u002Fwrite in English\n* Referred to supportive care service as an inpatient or outpatient\n* Rate anxiety as =\\\u003C 4 on ESAS-FS (Edmonton Symptom Assessment Scale-Financial Distress and Spiritual Pain)\n* Participants must agree to inhale isopropyl alcohol\n\nExclusion Criteria:\n\n* Received anti-emetics in the last 30 minutes\n* Received medical procedures (e.g. blood draws) which required exposure of isopropyl alcohol in the last 30 minutes\n* Inability to inhale through nares (including recent upper respiratory infection)\n* Known allergy to isopropyl alcohol\n* Delirium (i.e., score \\>= 7 on the Memorial Delirium Assessment Scale \\[MDAS\\])\n* Have never been on anti-emetics during the course of the treatment here (anti-emetic naive)",{"count":238,"type":21},112,[24],"The goal of this research study is to understand the effect of inhalation approaches in reducing nausea in cancer patients.",[27],"2026-05-26",{"date":244,"type":32},"2026-05-27",{"date":246,"type":21},"2026-11-05",{"date":248,"type":21},"2028-12-30",{"name":188,"class":128},{"id":251,"slug":4,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":4,"eligibilityCriteria":16,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":252,"targetDuration":4,"studyType":22,"phases":253,"briefSummary":25,"conditions":254,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":255,"lastUpdatePostDateStruct":256,"startDateStruct":258,"completionDateStruct":259,"leadSponsor":260,"locationsCount":261},"100591374",{"count":20,"type":21},[24],[27],"2026-05-11",{"date":257,"type":32},"2026-05-13",{"date":34,"type":32},{"date":36,"type":21},{"name":38,"class":39},55,{"id":263,"slug":264,"hasResults":12,"nctId":265,"briefTitle":266,"officialTitle":267,"acronym":4,"eligibilityCriteria":268,"healthyVolunteers":115,"sex":17,"minAge":269,"maxAge":270,"enrollmentInfo":271,"targetDuration":4,"studyType":22,"phases":272,"briefSummary":274,"conditions":275,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":277,"lastUpdatePostDateStruct":278,"startDateStruct":279,"completionDateStruct":281,"leadSponsor":283,"locationsCount":189},"100397280","a-study-to-see-if-an-iphone-weight-management-app-can-help-promote-weight-loss-in-adolescents-and-young-adults-after-a-stem-cell-transplant-100397280","NCT04453072","A Study to See if an iPhone Weight Management App Can Help Promote Weight Loss in Adolescents and Young Adults After a Stem Cell Transplant","Behavioral Weight Loss Intervention Utilizing Mobile Health Technology in Hematopoietic Stem Cell Transplant Patients (BWL001)","Inclusion Criteria:\n\n* Patients with a history of HSCT of any type, at least 100 days post-transplant at initial consultation of the study, will be eligible for the study\n* Patients must classify as obese, represented as body mass index (BMI) \\>= 85th percentile for age and gender\n* Patients must also be able to read English since the app intervention is only available in English form\n* No patients will be excluded for any specific underlying medical condition, but decisions will be made on a case by case basis if a patient's functioning is deemed to significantly interfere with intervention participation\n* PARENT:\n* His\u002Fher child meets all inclusion criteria\n* \\>= 18 years of age\n* Can speak English\n\nExclusion Criteria:\n\n* Patients who are \\\u003C 100 days post-transplant at initial consultation will not be eligible for the study, but may become eligible if they are \\> 100 days post-transplant at their next consultation that falls within the enrollment window\n* Patients whose BMI does not fall under the obese category will be excluded","13 Years","30 Years",{"count":50,"type":21},[273],"NA","This early phase I trial studies how well a behavioral weight loss intervention consisting of a smartphone application and coaching works for the promotion of weight loss in adolescents and young adults after a stem cell transplant. This study may help researchers learn more about how adolescents and young adults can lose weight and develop healthy eating habits.",[276,27],"Obesity","2026-05-07",{"date":255,"type":32},{"date":280,"type":32},"2020-07-01",{"date":282,"type":21},"2027-12-31",{"name":284,"class":128},"Jonsson Comprehensive Cancer Center",{"id":286,"slug":287,"hasResults":12,"nctId":288,"briefTitle":289,"officialTitle":290,"acronym":4,"eligibilityCriteria":291,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":292,"targetDuration":4,"studyType":22,"phases":294,"briefSummary":295,"conditions":296,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":306},"100579003","phase-1-a-study-to-evaluate-the-safety-and-efficacy-of-mk-3120-in-participants-with-advanced-solid-tumors-mk-3120-002-100579003","NCT06818643","A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002)","A Phase 1\u002F2 Open-label Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors","Inclusion Criteria:\n\n* Has a confirmed advanced (unresectable and\u002For metastatic) solid tumor and has received or been intolerant to all available treatments\n* If human immunodeficiency virus (HIV) positive, has well controlled HIV on antiretroviral therapy (ART)\n* If hepatitis B surface antigen (HBsAg) positive, must have received hepatitis B virus (HBV) antiviral therapy for at least 4 weeks and have undetectable HBV viral load\n* If hepatitis C virus (HCV) infected, must have undetectable HCV viral load\n\nExclusion Criteria:\n\n* Has active inflammatory bowel disease requiring immunosuppressive medication or previous history of inflammatory bowel disease\n* Has uncontrolled significant cardiovascular disease or cerebrovascular disease\n* Has history of documented severe dry eye syndrome, severe Meibomian gland disease and\u002For blepharitis, or severe corneal disease that prevents\u002Fdelays corneal healing\n* Has pleural effusion, ascites, and\u002For pericardial effusion that are symptomatic or require repeated drainage\n* Is HIV-positive and has a history of Kaposi's sarcoma and\u002For Multicentric Castleman's Disease\n* Known additional malignancy that is progressing or has required active treatment within the past 2 years\n* Known active central nervous system (CNS) metastases and\u002For carcinomatous meningitis\n* Active infection requiring systemic therapy, with exceptions\n* History of (noninfectious) pneumonitis\u002Finterstitial lung disease that required steroids or has current pneumonitis\u002Finterstitial lung disease\n* Has HBV or HCV infection",{"count":293,"type":21},270,[52,24],"Researchers are looking for new ways to treat people with certain advanced solid tumors. Advanced means the cancer has spread to other parts of the body and cannot be removed with surgery. Solid tumors are cancers mostly in body organs and tissues, not in the blood or other body liquids. The main goal of this study is to learn about the safety of MK-3120 and if people tolerate it.",[297,27],"Advanced Solid Tumors","2026-05-06",{"date":300,"type":32},"2026-05-08",{"date":302,"type":32},"2025-03-25",{"date":304,"type":21},"2031-03-25",{"name":38,"class":39},45,{"id":308,"slug":309,"hasResults":12,"nctId":310,"briefTitle":311,"officialTitle":312,"acronym":4,"eligibilityCriteria":313,"healthyVolunteers":12,"sex":17,"minAge":4,"maxAge":314,"enrollmentInfo":315,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":317,"conditions":318,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":336,"lastUpdatePostDateStruct":337,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":346},"100239986","project-every-child-for-younger-patients-with-cancer-100239986","NCT02402244","Project: Every Child for Younger Patients With Cancer","The Project: EveryChild Protocol: A Registry, Eligibility Screening, Biology and Outcome Study","Inclusion Criteria:\n\n* Enrollment must occur within 6 months of initial disease presentation OR within 6 months of refractory disease, disease progression, disease recurrence, second or secondary malignancy, or post-mortem\n* Patients previously enrolled on ACCRN07 are eligible to enroll on Tracking Outcome, Registry and Future Contact components of APEC14B1 any time after they reach age of majority\n* Patients with a known or suspected neoplasm that occurs in the pediatric, adolescent or young adult populations are eligible for enrollment as follows:\n\n  * All cancer cases with an International Classification of Diseases for Oncology (ICD-O) histologic behavior code of one \"1\" (borderline), two \"2\" (carcinoma in situ) or three \"3\" (malignant)\n  * All neoplastic lesions of the central nervous system regardless of behavior, i.e., benign, borderline or malignant\n  * All neoplastic lesions of the kidney regardless of behavior, i.e., benign, borderline or malignant\n  * The following other benign\u002Fborderline conditions:\n\n    * Mesoblastic nephroma\n    * Teratomas (mature and immature types)\n    * Myeloproliferative diseases including transient myeloproliferative disease\n    * Langerhans cell histiocytosis\n    * Lymphoproliferative diseases\n    * Desmoid tumors\n    * Gonadal stromal cell tumors\n    * Neuroendocrine tumors including pheochromocytoma\n    * Melanocytic tumors, except clearly benign nevi\n    * Ganglioneuromas\n* Subjects must be =\\\u003C 25 years of age at time of original diagnosis, except for patients who are being screened specifically for eligibility onto a COG (or COG participating National Clinical Trials Network \\[NCTN\\]) therapeutic study, for which there is a higher upper age limit\n* All patients or their parents or legally authorized representatives must sign a written informed consent and agree to participate in at least one component of the study; parents will be asked to sign a separate consent for their own biospecimen submission\n\n  * If patients or their parents or legally authorized representatives have not signed the Part A subject consent form at the time of a diagnostic bone marrow procedure, it is recommended that they initially provide consent for drawing extra bone marrow using the Consent for Collection of Additional Bone Marrow; consent using the Part A subject consent form must be provided prior to any other procedures for eligibility screening or banking under APEC14B1","25 Years",{"count":316,"type":21},75000,"This study gathers health information for the Project: Every Child for younger patients with cancer. Gathering health information over time from younger patients with cancer may help doctors find better methods of treatment and on-going care.",[319,320,321,322,323,324,325,326,327,328,329,27,330,331,332,333,334,335],"Adrenal Gland Pheochromocytoma","Carcinoma In Situ","Central Nervous System Neoplasm","Childhood Immature Teratoma","Childhood Kidney Neoplasm","Childhood Langerhans Cell Histiocytosis","Childhood Mature Teratoma","Congenital Mesoblastic Nephroma","Desmoid Fibromatosis","Ganglioneuroma","Lymphoproliferative Disorder","Malignant Solid Neoplasm","Melanocytic Neoplasm","Myeloproliferative Neoplasm","Neoplasm of Uncertain Malignant Potential","Neuroendocrine Neoplasm","Stromal Neoplasm","2026-05-01",{"date":338,"type":32},"2026-05-05",{"date":340,"type":32},"2015-11-03",{"date":342,"type":21},"2030-12-31",{"name":344,"class":345},"Children's Oncology Group","NETWORK",278,{"id":348,"slug":349,"hasResults":12,"nctId":350,"briefTitle":351,"officialTitle":352,"acronym":4,"eligibilityCriteria":353,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":354,"targetDuration":4,"studyType":22,"phases":356,"briefSummary":357,"conditions":358,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":361,"startDateStruct":363,"completionDateStruct":365,"leadSponsor":367,"locationsCount":84},"100517065","phase-1-nbm-bmx-administered-orally-to-patients-with-solid-tumors-or-newly-diagnosed-glioblastoma-100517065","NCT06012695","NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma","A Phase Ib\u002FII, Open-label Study of NBM-BMX as Monotherapy or in Combination With Radiotherapy and Temozolomide in Subjects With Solid Tumors or Newly Diagnosed Glioblastoma","Inclusion Criteria:\n\nArm A (advanced solid tumors)\n\n1. Having signed and dated the informed consent form.\n2. Females or males \\> 18 years old.\n3. Histologically or cytologically confirmed advanced solid tumors refractory to standard of care therapy, or for which no standard of care therapy is available.\n4. Disease that is measurable or evaluable as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 or Response Assessment in Neuro-Oncology (RANO) criteria (for CNS tumors).\n5. Eastern Cooperative Oncology Group (ECOG) performance status 0 to 2.\n6. Adequate organ function as defined by the following criteria:\n\n   1. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3 × upper limits of normal (ULN), unless liver metastases present, then ≤ 5 × ULN\n   2. Total serum bilirubin ≤ 1.5 × ULN unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin ≤ 3 × ULN\n   3. Absolute neutrophil count (ANC) ≥ 1,000\u002FμL\n   4. Platelets ≥ 75,000\u002FμL\n   5. Hemoglobin ≥ 8.0 g\u002FdL\n   6. Non-indexed estimated glomerular filtration rate (eGFR) ≥ 50 mL\u002Fmin\u002F1.73 m2 × BSA (m2)\u002F1.73.\n\n   Transfusion is not allowed to meet entry criteria.\n7. QTcF ≤ 480 msec\n8. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.\n\nArm B (newly diagnosed GBM)\n\n1. Having signed and dated the informed consent form.\n2. Females or males \\> 18 years old.\n3. Newly diagnosed, histologically confirmed glioblastoma, non-resectable, partially resected or resected.\n4. Karnofsky performance status (KPS) ≥ 60 at screening and before the initiation (Day 1) of concomitant therapy.\n5. Disease that is measurable or evaluable as defined by Response Assessment in Neuro-Oncology (RANO) criteria.\n6. Adequate organ function as defined by the following criteria:\n\n   1. Serum aspartate transaminase (AST) and serum alanine transaminase (ALT) ≤ 3 × upper limit of normal (ULN), unless liver metastases present, then ≤ 5 × ULN\n   2. Total serum bilirubin ≤ 1.5 × ULN unless bilirubin elevation is related to Gilbert's Syndrome for which bilirubin ≤ 3 × ULN\n   3. Absolute neutrophil count (ANC) ≥ 1,500\u002FμL\n   4. Platelets ≥ 100,000\u002FμL\n   5. Hemoglobin ≥ 8.0 g\u002FdL\n   6. Non-indexed estimated glomerular filtration rate (eGFR) ≥ 60 mL\u002Fmin\u002F1.73 m2 × BSA (m2)\u002F1.73.\n\n   Transfusion is not allowed to meet entry criteria.\n7. QTcF ≤ 480 msec\n8. Willingness and ability to comply with the study scheduled visits, treatment plans, laboratory tests and other procedures.\n\nExclusion Criteria:\n\nArm A (advanced solid tumors)\n\n1. Systemic anti-cancer treatment (investigational or approved) within 28 days or 5 half-lives of that drug (whichever is shorter) of the first dose of NBM-BMX.\n2. Curative radiation therapy within 28 days or palliative RT within 7 days of the first dose of NBM-BMX.\n3. Currently taking strong inhibitors (e.g., gemfibrozil) or inducers of CYP2C8.\n4. Any of the following within 6 months of the first dose of NBM-BMX: pulmonary embolism events, deep vein thrombosis (DVT) events, myocardial infarction, severe\u002Funstable angina, coronary\u002Fperipheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack.\n5. A positive test for hepatitis B (HBsAg) and\u002For hepatitis C (anti-HCV antibody), unless the HBV DNA level and\u002For HCV RNA level is below the limit of detection.\n6. Known history of human immunodeficiency virus (HIV) infection.\n7. Men and women of childbearing potential who are unwilling to use highly effective contraceptive methods during the study period.\n\n   Highly effective contraceptive methods include implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs), sexual abstinence, surgical sterilization or a partner who is sterile.\n8. Females who are pregnant or breastfeeding.\n9. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart, in the judgement of the investigator and\u002For sponsor, excess risks associated with study participation or study drug administration.\n\nArm B (newly diagnosed GBM)\n\n1. Prior systemic therapy (including Gliadel wafer implant), immunotherapy, investigational agents, or radiotherapy for glioblastoma.\n2. Currently taking strong inhibitors (e.g., gemfibrozil) or inducers of CYP2C8.\n3. Corticosteroid use of \\> 8 mg\u002Fday dexamethasone or equivalent within 5 days before the first dose of NBM-BMX.\n4. A history of hypersensitivity reaction to temozolomide or dacarbazine.\n5. Any of the following within 6 months of the first dose of NBM-BMX: pulmonary embolism events, deep vein thrombosis (DVT) events, myocardial infarction, severe\u002Funstable angina, coronary\u002Fperipheral artery bypass graft, congestive heart failure, or cerebrovascular accident including transient ischemic attack.\n6. A positive test for hepatitis B (HBsAg) and\u002For hepatitis C (anti-HCV antibody), unless the HBV DNA level and\u002For HCV RNA level is below the limit of detection.\n7. Known history of human immunodeficiency virus (HIV) infection. Note: HIV testing is not required.\n8. Men and women of childbearing potential who are unwilling to use highly effective contraceptive methods during the study period and for at least 6 months after the final dose of temozolomide.\n\n   Highly effective contraceptive methods include implants, injectables, combined oral contraceptives, intra-uterine devices (IUDs), sexual abstinence, surgical sterilization or a partner who is sterile.\n9. Female who are pregnant or breastfeeding.\n10. Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that would impart, in the judgement of the investigator and\u002For sponsor, excess risks associated with study participation or study drug administration.",{"count":355,"type":21},79,[52,24],"NBM-BMX is an orally available new chemical entity to inhibit histone deacetylases 8 (HDAC8) activity specifically, being developed as a potential anti-cancer therapeutic by NatureWise. This study aims to evaluate the safety, pharmacokinetics, and preliminary efficacy of NBM-BMX as monotherapy in subjects with advanced solid tumors or combination with the standard of care treatment in subjects with newly diagnosed glioblastoma.",[27,359],"Malignant Neoplasm of Brain","2026-04-24",{"date":362,"type":32},"2026-04-29",{"date":364,"type":32},"2023-08-11",{"date":366,"type":21},"2029-09-30",{"name":368,"class":39},"Novelwise Pharmaceutical Corporation",{"id":370,"slug":371,"hasResults":12,"nctId":372,"briefTitle":373,"officialTitle":374,"acronym":4,"eligibilityCriteria":375,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":376,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":378,"conditions":379,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":360,"lastUpdatePostDateStruct":381,"startDateStruct":382,"completionDateStruct":384,"leadSponsor":386,"locationsCount":189},"100283474","norris-orien-total-cancer-care-100283474","NCT02970045","Norris ORIEN Total Cancer Care","Norris ORIEN Total Cancer Care Protocol: A Lifetime Partnership With Patients","Inclusion Criteria:\n\n* Limited to those patients who are registered for outpatient or inpatient care at University of Southern California (USC) Norris\n* Able to understand and sign the TCCP informed consent, California subject's bill of rights, Health Insurance Portability and Accountability Act (HIPAA), and research authorization form directly or through an authorized representative; the informed consent, subject's bill of rights, HIPAA, and research authorization will be available in both English and Spanish languages\n\nExclusion Criteria:\n\n* Individuals who are not registered as patients for outpatient or inpatient care at USC Norris\n* Individuals who are unable to understand or sign the TCCP informed consent, subject's bill of rights, HIPAA, and research authorization in either English or Spanish",{"count":377,"type":21},10000,"This research trial collects biological samples and clinical information to create a repository of data from patients with cancer or a predisposition for cancer. Combining genetic information from biological samples and clinical data may lead to more knowledge about why certain cancers respond to treatment and help create more personalized medicine.",[380,27],"Cancer Risk",{"date":362,"type":32},{"date":383,"type":32},"2016-05-02",{"date":385,"type":21},"2037-05-02",{"name":387,"class":128},"University of Southern California",{"id":389,"slug":390,"hasResults":12,"nctId":391,"briefTitle":392,"officialTitle":393,"acronym":4,"eligibilityCriteria":394,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":395,"enrollmentInfo":396,"targetDuration":4,"studyType":22,"phases":398,"briefSummary":399,"conditions":400,"keywords":401,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":409,"startDateStruct":410,"completionDateStruct":412,"leadSponsor":414,"locationsCount":229},"100545747","phase-1-a-study-of-tsn1611-treating-patients-with-advanced-solid-tumors-harboring-kras-g12d-mutation-100545747","NCT06385925","A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation","Phase 1\u002F2 Study of TSN1611 in Subjects With Advanced Solid Tumors Harboring KRAS G12D Mutation","Subjects must meet all the following inclusion criteria to be eligible for participation in this study:\n\n* The subject fully understands the requirements of the study and voluntarily signs the ICF.\n* At least 18 years of age at the time of informed consent.≤ 75 years of age for Cohort B and C.\n* Life expectancy of 3 months or more.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.\n* Phase 1 part (1a\u002F1b) of Monotherapy:\n\nSubjects with histologically or cytologically confirmed locally advanced or metastatic solid tumor harboring KRAS G12D mutation; subjects must be refractory or intolerable to standard treatment, or have no standard treatment available, or the subject is ineligible or declines standard treatment.\n\nPhase 2 part of TSN1611 Monotherapy:\n\nSubjects with histologically or cytologically confirmed locally advanced or metastatic PDAC、CRC and NSCLC harboring KRAS G12D mutation; According to the requirements of different combined cohorts, the number of previous treatments is taken into account.\n\n• Patients with adequate cardiac, liver, renal function, etc.\n\nExclusion Criteria\n\nSubjects will be excluded if they meet any of the following criteria:\n\n* Leptomeningeal disease or Active central nervous system (CNS) metastases.\n* Prior systemic anti-cancer treatment within 21 days or 5 half-lives (whichever is shorter will be used as the criteria) prior to the first dose of study drug.\n* Radical radiation within 4 weeks prior to the first dose of study drug; palliative radiotherapy within 1 week prior to the first dose of study drug.\n* Any unresolved Grade 2 or higher toxicity from previous anticancer therapy except alopecia.\n* Has participated in a study of investigational agent and received the investigational agent within 21 days or 5 half-lives, if known (whichever is shorter) prior to the first dose of study drug.\n* History of interstitial lung disease (ILD), drug induced IDL, or current active pneumonitis, radiation pneumonitis requiring therapeutic intervention, or uncontrolled other lung disease.\n* Any of the following in the past 6 months: myocardial infarction, unstable angina, symptomatic congestive heart failure, stroke or transient ischemic attack, pulmonary embolism.\n* Prior treatment with KRAS G12D targeted therapy.\n* Has a history or current evidence of any severe condition, concurrent therapy, or laboratory abnormality that might confound the interpretation of the study results, interfere with the subject's participation for the full duration of the trial, or is not in the best interest of the subject to participate, in the opinion of the investigator.","75 Years",{"count":397,"type":21},440,[52,24],"The study is a first-in-human (FIH), open-label, multi-center phase 1\u002F2 study of TSN1611 in subjects with KRAS G12D mutant advanced solid tumors. This study will consist of a phase 1 dose escalation part and phase 2 dose expansion part. This study will evaluate the efficacy of TSN1611 at RP2D(s) through ORR using RECIST version 1.1, and determine and confirm the MTD\u002FRP2D for TSN1611 in combination with cetuximab, in combination with cetuximab and mFOLFOX6, in combination with gemcitabine and albumin-bound paclitaxel in subjects with selected solid tumors.",[27],[402,403,404,405,406,407],"solid tumor","KRAS G12D mutation","pancreatic cancer","colorectal cancer","non-small cell lung cancer","malignant neoplasm","2026-04-21",{"date":360,"type":32},{"date":411,"type":32},"2024-04-29",{"date":413,"type":21},"2027-04-30",{"name":415,"class":39},"Tyligand Pharmaceuticals (Suzhou) Limited",{"id":417,"slug":418,"hasResults":12,"nctId":419,"briefTitle":420,"officialTitle":421,"acronym":4,"eligibilityCriteria":422,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":423,"targetDuration":4,"studyType":22,"phases":424,"briefSummary":425,"conditions":426,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":408,"lastUpdatePostDateStruct":428,"startDateStruct":429,"completionDateStruct":431,"leadSponsor":433,"locationsCount":189},"100420238","phase-2-intraoperative-tumor-margin-identification-with-icg-dye-imaging-100420238","NCT04752137","Intraoperative Tumor Margin Identification With ICG Dye Imaging","Evaluation of Intraoperative Tumor Margin Identification With Fluorescent Dye Imaging","Inclusion Criteria:\n\n* All patients 18 years of age or older who present to Massachusetts General Hospital Department of Orthopaedic Surgery with a benign or malignant bone or soft tissue mass that is consented for surgery during the study period.\n\nExclusion Criteria:\n\n* Pregnant or nursing patients\n* Patients with previously known anaphylaxis to IV contrast or iodine (other allergies may be considered on a case-by-case basis)\n* Patients in renal failure who are not cleared for ICG administration by their primary physician or oncologist",{"count":171,"type":21},[24],"In this research study we want to learn more about the use of indocyanine green (ICG) during bone or soft tissue mass resections. Indocyanine green (ICG) is a type of dye that is used in medical diagnostics. We want to determine if ICG-guided tumor resection is more effective in obtaining negative margins. Lastly, we want to assess traditional oncologic outcomes of local recurrence, time to metastatic disease, and overall and disease specific survival.",[427,27],"Benign Neoplasm",{"date":360,"type":32},{"date":430,"type":32},"2022-05-25",{"date":432,"type":21},"2030-04-01",{"name":434,"class":128},"Massachusetts General Hospital",{"id":436,"slug":437,"hasResults":12,"nctId":438,"briefTitle":439,"officialTitle":440,"acronym":4,"eligibilityCriteria":441,"healthyVolunteers":12,"sex":17,"minAge":442,"maxAge":4,"enrollmentInfo":443,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":445,"conditions":446,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":447,"lastUpdatePostDateStruct":448,"startDateStruct":450,"completionDateStruct":452,"leadSponsor":454,"locationsCount":456},"100261895","targeted-genomic-analysis-of-blood-and-tissue-samples-from-patients-with-cancer-100261895","NCT02688517","Targeted Genomic Analysis of Blood and Tissue Samples From Patients With Cancer","Targeted Genomic Analysis of Human Cancers","Inclusion Criteria:\n\n* Karnofsky\u002FLansky performance score \\>= 30\n* A signed written informed consent\n* Evaluation in surgical\u002Fmedical\u002Fradiation oncology\u002Fradiology clinic, with a history of biopsy-confirmed diagnosis of cancer of rare histology and\u002For poor prognosis with standard therapy; priority will be given to rare cancers with poor prognosis and lack of effective standard therapy; study principal investigator (PI) or designee will review and approve each case before enrollment\n* Paraffin blocks of the patient's tumor tissue are available and accessible for analysis\n\nExclusion Criteria:\n\n* Karnofsky\u002FLansky performance score \\\u003C 30\n* Life expectancy \\\u003C 3 months","1 Year",{"count":444,"type":21},1100,"This research trial studies the use of targeted genomic analysis of blood and tissue samples from patients with cancer. Genomic sequencing is a laboratory method that is used to determine the entire genetic makeup of a specific organism or cell type. Genomic sequencing can be used to find changes in areas of the genome that may be important in the development of cancer. It may also help doctors improve ways to diagnose and treat patients with rare cancers with poor prognosis or lack of effective therapy.",[27],"2026-04-14",{"date":449,"type":32},"2026-04-17",{"date":451,"type":4},"2013-02",{"date":453,"type":21},"2030-05",{"name":455,"class":128},"Rutgers, The State University of New Jersey",11,{"id":458,"slug":459,"hasResults":12,"nctId":460,"briefTitle":461,"officialTitle":462,"acronym":4,"eligibilityCriteria":463,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":464,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":466,"conditions":467,"keywords":471,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":474,"startDateStruct":476,"completionDateStruct":478,"leadSponsor":480,"locationsCount":189},"100630454","cadherin-3cdh3-targeted-pet-in-lung-malignant-tumors-100630454","NCT07487883","Cadherin 3(CDH3)-Targeted PET in Lung Malignant Tumors","A Single-arm, Open-label, Single-center Clinical Study to Evaluate CDH3-targeted Positron Emission Tomography (PET) for Lung Malignant Tumors","Inclusion Criteria:\n\n1. Age ≥ 18 years, male or female, with an ECOG performance status of 0 or 1;\n2. Availability of complete clinical and imaging data;\n3. Life expectancy ≥ 12 weeks;\n4. Hematology, liver and kidney function meeting the following criteria: Hematology: WBC ≥ 4.0 × 10⁹\u002FL or neutrophils ≥ 1.5 × 10⁹\u002FL, PLT ≥ 100 × 10⁹\u002FL, Hb ≥ 90 g\u002FL; PT or APTT ≤ 1.5 × ULN; Liver and kidney function: T-Bil ≤ 1.5 × ULN, ALT\u002FAST ≤ 2.5 × ULN, ALP ≤ 2.5 × ULN; BUN ≤ 1.5 × ULN, SCr ≤ 1.5 × ULN;\n5. Patients who have not received radiotherapy or chemotherapy and are eligible for surgical resection or biopsy to obtain a pathological diagnosis, or those highly suspected of having malignant pulmonary nodules according to clinical diagnostic criteria;\n6. Pathologically confirmed lung cancer via biopsy before neoadjuvant therapy; life expectancy ≥ 12 weeks;\n7. Ability to provide adequate tumor tissue for testing and research.\n\nExclusion Criteria:\n\n1. Women who are planning pregnancy, pregnant, or breastfeeding;\n2. History of other malignant tumors or prior receipt of other anti-tumor therapies;\n3. Poor or missing PET scan image quality of the probe that fails to meet analysis standards;\n4. Presence of claustrophobia or other mental illnesses;\n5. Any other conditions deemed by the investigators as inappropriate for participation in this study.",{"count":465,"type":21},80,"Lung malignant tumors are a significant health threat with high incidence and mortality rates, and molecular imaging is crucial for early diagnosis, staging, prognosis evaluation, and therapeutic efficacy assessment. 18F-FDG PET imaging is widely used, but has limitations. CDH3 is a promising target for tumor-targeted imaging, as it is only expressed in cancerous epithelial cells. A new PET probe, 68Ga-TOI-1, targeting CDH3 has been developed with better affinity and selectivity than previous probes. Preclinical data support its safety and metabolic stability, and future research will explore its diagnostic and staging value in different types of lung tumors, providing a new and precise evaluation method for lung malignant tumors.",[468,27,469,470],"Non-Small Cell Lung Cancer","Pulmonary Nodules","PET\u002FCT",[27,470,468,472],"Pulmonary nodules","2026-03-27",{"date":475,"type":32},"2026-04-02",{"date":477,"type":32},"2026-03-18",{"date":479,"type":21},"2027-07-30",{"name":481,"class":128},"Peking University People's Hospital",{"id":483,"slug":484,"hasResults":12,"nctId":485,"briefTitle":486,"officialTitle":487,"acronym":4,"eligibilityCriteria":488,"healthyVolunteers":115,"sex":17,"minAge":489,"maxAge":4,"enrollmentInfo":490,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":492,"conditions":493,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":473,"lastUpdatePostDateStruct":498,"startDateStruct":499,"completionDateStruct":501,"leadSponsor":502,"locationsCount":189},"100301727","collection-of-immunology-specimens-from-patients-with-cancer-or-blood-disorders-and-healthy-volunteers-100301727","NCT03207854","Collection of Immunology Specimens From Patients With Cancer or Blood Disorders, and Healthy Volunteers","Protocol for Immunology Specimen Collection From Cancer Patients, Patients With Hematologic Diagnoses, and Healthy Normal Controls","Inclusion Criteria:\n\n* All patients known to have cancer, an immune-mediated hematologic diagnosis, or a healthy normal volunteer\n* Definition of immune-mediated hematologic diagnosis: diagnoses for which immune dysfunction and\u002For immune system directed therapy (eg. aplastic anemia, autoimmune hemolytic anemia, immune thrombocytopenic purpura \\[ITP\\], etc.) are involved\n* Definition of healthy normal volunteer: persons lacking diagnoses of any type of cancer, diabetes, cardiovascular diseases, non-hematologic autoimmune disease (eg. systemic lupus erythematosus \\[SLE\\], rheumatoid arthritis \\[RA\\], Crohn's disease) and not taking any immunosuppressive medications\n* Patients must have been seen in the Norris Hospital and outpatient clinics, or the Los Angeles County (LAC)-University of Southern California (USC) Medical Center or outpatient clinics; healthy volunteers can be recruited without any physician visit appointments since their labs are strictly for clinical research and not for personal health issues unrelated to the project\n\nExclusion Criteria:\n\n* Unable to give informed consent to specimen collection\n* Known human immunodeficiency virus (HIV) positive status\n* Persons taking any type of immunosuppressive medication are excluded from participating as healthy normal volunteers\n* Any patient for whom specimen collection is judged to be unsafe (for example, for patients unable to establish venous access)","19 Years",{"count":491,"type":21},625,"This research trial collects and stores blood, tissue, and bone marrow specimens from patients with cancer or blood disorders, and healthy volunteers to study the immune system in a variety of different types of experiments, as well as associated clinical data as appropriate, focused on understanding mechanisms of immunotherapy.",[494,495,496,497,27],"Healthy Subject","Hematologic and Lymphocytic Disorder","Hematopoietic and Lymphoid Cell Neoplasm","Immune System Disorder",{"date":475,"type":32},{"date":500,"type":32},"2017-04-12",{"date":282,"type":21},{"name":387,"class":128},{"id":504,"slug":505,"hasResults":12,"nctId":506,"briefTitle":507,"officialTitle":507,"acronym":4,"eligibilityCriteria":508,"healthyVolunteers":12,"sex":17,"minAge":18,"maxAge":509,"enrollmentInfo":510,"targetDuration":512,"studyType":118,"phases":4,"briefSummary":513,"conditions":514,"keywords":516,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":521,"lastUpdatePostDateStruct":522,"startDateStruct":524,"completionDateStruct":526,"leadSponsor":528,"locationsCount":189},"100603014","construction-and-evaluation-of-tumor-immunotherapy-and-organ-damage-early-warning-system-based-on-multi-omics-100603014","NCT07131007","Construction and Evaluation of Tumor Immunotherapy and Organ Damage Early Warning System Based on Multi-omics","Inclusion Criteria:\n\n· Patients with cancer who are receiving immune checkpoint inhibitor treatment.\n\nExclusion Criteria:\n\n* Active phase of severe autoimmune disease.\n* Severe organ dysfunction.\n* Presence of active infection.\n* Pregnancy or lactation.\n* Allergy to drug components.","80 Years",{"count":511,"type":21},2000,"48 Months","This project is based on the in-depth analysis and integration of multi-omics data, including but not limited to genomics, transcriptomics, proteomics, and metabolomics. It aims to construct a comprehensive early-warning system for organ function damage in immune-related adverse events (irAEs) associated with immune checkpoint inhibitors (ICIs) during tumor immunotherapy. The core objective of this system is to enhance the overall safety and efficacy of tumor immunotherapy.\n\nFirst, the project leverages a database to mine the differential omics data of tumor immunotherapy patients with combined organ dysfunction (including combined and non-combined severe infections) within the scope of this project. By integrating biochemical indicators and related hemodynamic data, it constructs a risk early-warning system for organ damage in patients undergoing tumor immunotherapy, while verifying its clinical value and guiding significance.\n\nThe specific contents mainly include: capturing specific molecules of organ damage in severe patients after tumor immunotherapy, screening genes, proteins, and metabolic products related to organ damage (including the heart, lungs, brain, liver, kidneys, gastrointestinal tract, etc.), and identifying new specific organ damage biomarkers under different pathogenic factors such as tumor immunotherapy, infections, and irAEs. It collects general clinical information, biochemical indicators, and hemodynamic indicators, and combines multi-omics data to establish an organ damage prediction model. Machine learning algorithms are used for optimization to construct an early-warning system.\n\nModel optimization within the system will be carried out, along with prospective clinical research and multi-dimensional verification. By evaluating the accuracy and cost-effectiveness of the model, it provides decision-making support for clinicians and promotes the development of personalized treatment.",[27,515],"Organ Damage",[517,518,519,520],"Tumor immunotherapy","Immune checkpoint inhibitors","Immune - related adverse events","organ damage","2026-03-19",{"date":523,"type":32},"2026-03-23",{"date":525,"type":32},"2025-09-15",{"date":527,"type":21},"2029-01-01",{"name":529,"class":128},"Hebei Medical University Fourth Hospital",{"id":531,"slug":532,"hasResults":12,"nctId":533,"briefTitle":534,"officialTitle":535,"acronym":536,"eligibilityCriteria":537,"healthyVolunteers":12,"sex":17,"minAge":442,"maxAge":4,"enrollmentInfo":538,"targetDuration":4,"studyType":22,"phases":540,"briefSummary":542,"conditions":543,"keywords":562,"overallStatus":202,"whyStopped":4,"lastUpdateSubmitDate":580,"lastUpdatePostDateStruct":581,"startDateStruct":583,"completionDateStruct":585,"leadSponsor":587,"locationsCount":589},"100626796","phase-2-determine-trial-treatment-arm-07-dabrafenib-in-combination-with-trametinib-in-adult-paediatric-and-teenageyoung-adult-patients-with-braf-v600-mutation-positive-cancers-100626796","NCT07440290","DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage\u002FYoung Adult Patients With BRAF V600 Mutation-Positive Cancers.","DETERMINE (Determining Extended Therapeutic Indications for Existing Drugs in Rare Molecularly Defined Indications Using a National Evaluation Platform Trial): An Umbrella-Basket Platform Trial to Evaluate the Efficacy of Targeted Therapies in Rare Adult, Paediatric and Teenage\u002FYoung Adult (TYA) Cancers With Actionable Genomic Alterations, Including Common Cancers With Rare Actionable Alterations. Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and TYA Patients With BRAF V600 Mutation-Positive Cancers.","DETERMINE","THE PATIENT MUST FULFIL THE ELIGIBILITY CRITERIA WITHIN THE DETERMINE MASTER PROTOCOL (NCT05722886) AND WITHIN THE TREATMENT ARM 07 (DABRAFENIB AND TRAMETINIB) OUTLINED BELOW\\* \\*When dabrafenib- and trametinib-specific inclusion\u002Fexclusion criteria or precautions below differ from those specified in the Master Protocol, the dabrafenib- and trametinib-specific criteria will take precedence.\n\nInclusion criteria:\n\nA. Confirmed diagnosis of a malignancy harbouring an oncogenic alteration in BRAF V600, including Langerhans cell histiocytosis, using an analytically validated next-generation sequencing method.\n\nB. Patients ≥1 year old and ≥8 kg in body weight.\n\nC. Women of childbearing potential are eligible provided that they meet the following criteria:\n\n• Have a negative serum or urine pregnancy test before enrolment and;\n\n• Agree to use one form of a non-hormonal highly effective contraception method (a method that can achieve a failure rate of \\\u003C1% when used consistently and correctly; the requirement for non-hormonal method is because dabrafenib may decrease the efficacy of oral or any systemic hormonal contraceptives), such as: i. intrauterine device (IUD), ii. bilateral tubal occlusion, bilateral tubal ligation (at least six weeks before taking trial treatment), iii. vasectomised partner, iv. total sexual abstinence. Effective from the first administration of dabrafenib and trametinib (whichever is first), throughout the trial and for two weeks following discontinuation of dabrafenib and for 16 weeks following discontinuation of trametinib (whichever is later).\n\nPatients who are breastfeeding must be willing to discontinue breastfeeding from the start of treatment, throughout the trial and for two weeks following discontinuation of dabrafenib and for 16 weeks following discontinuation of trametinib (whichever is later).\n\nD. Male patients with partners who are women of childbearing potential are eligible provided that they agree to the following, from the first administration of dabrafenib and trametinib (whichever is first), throughout the trial and for two weeks after the last administration of dabrafenib and 16 weeks after the last administration of trametinib (whichever is later):\n\n* Agree to take measures not to father children by using a barrier method of contraception (male condom plus spermicide) or to sexual abstinence.\n* Non-vasectomised male partners with partners who are women of childbearing potential should also be advised of the benefit for their partner of using a highly effective method of contraception, such as:\n\n  i. combined (oestrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation \\[oral, intravaginal or transdermal\\]), ii. progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable or implantable), iii. IUD, iv. intrauterine hormone-releasing system (IUS), v. bilateral tubal occlusion, vi. total sexual abstinence.\n* Male patients with pregnant or breastfeeding partners must be advised to use barrier method contraception (male condom) to prevent drug exposure of the foetus or neonate, even if vasectomised.\n* Male patients must refrain from donating sperm for the same period.\n\nE. Patients must be able and willing to undergo a fresh tissue biopsy at baseline and blood samples for translational research. Note that for patients with haematological malignancies or neuroblastomas, blood, bone marrow aspiration and\u002For trephine or lymph node biopsy samples may be taken.\n\nF. Adequate organ function as per haematological and biochemical indices within the ranges defined in the protocol. These measurements should be performed to confirm the patient's eligibility\n\nExclusion criteria:\n\nA. Diagnosis of one of the following BRAF V600E mutation-positive cancers:\n\n* Colorectal cancer in adult (≥18 years) patients;\n* Unresectable or metastatic melanoma in adult (≥18 years) patients;\n* Advanced non-small cell lung cancer in adult (≥18 years) patients;\n* Gliomas harbouring a BRAF V600E mutation in paediatric (1 to \\\u003C16 years) or TYA (16 to \\\u003C18 years) patients.\n\nB. Previous treatment with dabrafenib and trametinib in combination (or other BRAF and MEK inhibitors in combination) for the current indication.\n\nC. Female patients who are pregnant, breastfeeding or planning to become pregnant during the trial or for two weeks following their last dose of dabrafenib or 16 weeks following their last dose of trametinib, whichever is later.\n\nD. Known hypersensitivity to dabrafenib or trametinib or any of the excipients. See the current relevant SmPCs (UK) for the full lists.\n\nE. Patients with a history of retinal vein occlusion.\n\nF. Any impairment of gastrointestinal (GI) function of uncontrolled GI disease that may significantly alter the administration or absorption of dabrafenib and\u002For trametinib (e.g. history of diverticulitis, metastases to the GI tract, uncontrolled Crohn's disease, uncontrolled ulcerative diseases, uncontrolled nausea, vomiting, diarrhoea, malabsorption syndrome or short gut syndrome).\n\nG. Clinically significant cardiac or cerebrovascular disease as defined by:\n\n* Unstable angina within three months prior to screening;\n* Myocardial infarction within three months prior to screening;\n* History of documented congestive heart failure (New York Heart Association functional classification III\u002FIV) etc.\n\nPatients with a cerebrovascular event (including stroke or transient ischaemic attack \\[TIA\\]) within three months prior to screening.\n\n• Patients with primary central nervous system (CNS) tumours may be considered unless intratumoural bleeding has occurred within two weeks prior to the first dose of dabrafenib and trametinib, and patients with punctate CNS haemorrhages \\\u003C3 mm may be considered.\n\nH. Patients who were administered a live, attenuated vaccine within 28 days prior to initiation of treatment, or anticipation of need for such a vaccine during investigational medicinal product (IMP) treatment or within six months after the final dose of dabrafenib and trametinib.\n\nI. Known active infections (bacterial, fungal or viral) that would interfere with the assessment of safety or efficacy of dabrafenib and trametinib including human immunodeficiency virus (HIV) positivity. Patients with history of testing positive for HIV infection are eligible provided that each of the following conditions are met:\n\n* CD4 count ≥350\u002FµL;\n* Undetectable viral load;\n* Receiving antiretroviral therapy (ART) that does not interact with IMP (patients should be on established ART for at least four weeks); and\n* No HIV\u002Facquired immune deficiency syndrome associated opportunistic infection in the last 12 months.\n\nJ. Any clinically significant concomitant disease or condition (or its treatment) that could interfere with the conduct of the trial (including absorption of oral medications) that would, in the opinion of the Investigator, pose an unacceptable risk to the patient in this trial.",{"count":539,"type":21},30,[24,541],"PHASE3","This clinical trial is looking at two drugs called dabrafenib and trametinib. Dabrafenib and trametinib are approved as standard of care treatment for adult patients with melanoma (a type of skin cancer) or lung cancer and in children with glioma (a type of brain tumour). This means they have gone through clinical trials and been approved by the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK. Dabrafenib and trametinib work in patients with a particular mutation in their cancer known as BRAF V600.\n\nInvestigators now wish to find out if they will be useful in treating patients with other cancer types which have the same mutation. If the results are positive, the study team will work with the NHS and the Cancer Drugs Fund to see if these drugs can be routinely accessed for patients in the future.\n\nThis trial is part of a trial programme called DETERMINE. The programme will also look at other anti-cancer drugs in the same way, through matching the drug to rare cancer types or ones with specific mutations.",[544,27,545,546,547,548,549,550,551,552,553,554,555,556,557,558,559,560,561],"Haematological Malignancy","Lymphoproliferative Disorders","Neoplasms by Histologic Type","Neoplasms by Site","Gastrointestinal Cancer","Non-Melanoma Skin Cancer (NMSC)","Langerhans Cell Histiocytosis (LCH)","Cancer","Erdheim-Chester Disease","Thyroid Carcinoma, Papillary","Ovarian Neoplasms","Colorectal Neoplasms","Laryngeal Neoplasms","Carcinoma, Non-Small Cell-Lung","Glioma","Multiple Myeloma","Thyroid Carcinoma, Anaplastic","Solid Tumour",[563,564,551,565,566,567,568,569,570,571,547,572,573,574,575,576,577,578,579],"Adult","Antineoplastic Agents","Child","Dabrafenib","Malignancy","Malignant Neoplasms","Molecular Targeted Therapy","Mutation","Neoplasms by Histologic Site","Paediatric","Precision Medicine","Proto-Oncogene Proteins B-raf","Protein Kinase Inhibitors","Rare","Trametinib","Tumour-Agnostic","Young adult","2026-02-23",{"date":582,"type":32},"2026-02-27",{"date":584,"type":21},"2026-02",{"date":586,"type":21},"2029-10",{"name":588,"class":128},"Cancer Research UK",27,{"id":591,"slug":592,"hasResults":12,"nctId":593,"briefTitle":594,"officialTitle":595,"acronym":4,"eligibilityCriteria":596,"healthyVolunteers":115,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":597,"targetDuration":4,"studyType":118,"phases":4,"briefSummary":599,"conditions":600,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":604,"lastUpdatePostDateStruct":605,"startDateStruct":607,"completionDateStruct":609,"leadSponsor":611,"locationsCount":189},"100095591","new-assessment-system-in-measuring-symptom-distress-in-cancer-patients-100095591","NCT00505245","New Assessment System in Measuring Symptom Distress in Cancer Patients","Measuring the Symptom Distress of Cancer Patients: Development of a New Assessment System","Inclusion Criteria:\n\n* NORMAL SAMPLES: Community dwelling adults 18 years of age or older\n* PATIENT SAMPLES: Inpatients and outpatients 18 years of age or older, being followed at UT MD Anderson\n* EXPERT PANEL PROFESSIONAL PARTICIPANTS: Physician or other healthcare provider with at least 5 years of experience caring for patients with the disease and\u002For treatment of interest, at least one publication in the last 5 years dealing with the disease and\u002For treatment of interest (physician only), ability to speak and read English, consent to participate\n* EXPERT PANEL FAMILY CAREGIVERS PARTICIPANTS: Identification as a family caregiver by patient enrolled as expert panel participant with the disease and\u002For treatment of interest, 18 years of age or older, ability to speak and read English, consent to participate\n* EXPERT PANEL PATIENT PARTICIPANTS: Patient with identified family caregiver participating on Expert Panel, willingness to receive packet for expert panel participation\n\nExclusion Criteria:\n\n* EXPERT PANEL PATIENT PARTICIPANTS: Patient with identified family caregiver participating on expert panel, willingness to receive packet for expert panel participation",{"count":598,"type":21},6500,"This trial studies how well a new assessment system (MDASI or other MD Anderson-developed PRO instrument) works in measuring symptoms and the impact on quality of life in cancer patients. Development of a new assessment system may provide more information about the common symptoms that may occur in patients due to cancer and its treatment and how the symptoms impact quality of life.",[601,602,27,603],"Caregiver","Health Care Provider","Physician","2026-01-20",{"date":606,"type":32},"2026-01-21",{"date":608,"type":32},"1999-04-13",{"date":610,"type":21},"2031-04-30",{"name":188,"class":128}]